期刊
LEUKEMIA RESEARCH
卷 33, 期 2, 页码 232-236出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2008.06.003
关键词
Myelodysplastic syndrome; Beta 2 microglobulin; Prognosis
We evaluated the relevance of beta 2 microglobulin (B2M) plasma concentration in 109 patients with myelodysplastic syndrome (MDS) front the Duesseldorf registry. Sixty-five patients with B2M level >= 2 mg/dl showed a significantly lower overall survival time with a median of 23 in comparison to 61 months for 44 patients with B2M below 2 mg/dl, The risk of AML evolution was higher in patients with B2M >= 2 mg/dl. Using multivariate analysis We found the B2M level at the time of diagnosis to be an independent prognostic parameter for survival and for the risk of developing AML in high-risk MDS patients. (C) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据